Statute Details
- Title: Health Products (Active Ingredients) Regulations 2023
- Act Code: HPA2007-S831-2023
- Legislative Type: Subsidiary legislation (SL)
- Authorising Act: Health Products Act 2007
- Enacting Authority: Health Sciences Authority (HSA), with Minister for Health approval
- Commencement: 18 December 2023 (as stated in regulation 1)
- Current Version: “Current version as at 27 Mar 2026” (per the provided extract)
- Key Provisions (by topic): Prohibitions (Parts 2), licensing (Part 3), duties (Part 4), certificates (Part 5), enforcement and procedure (Part 6)
- Key Definitions: “appropriate non-proprietary name”, “manufacture”, “Good Manufacturing Practice standard”, “Good Distribution Practice standard”, “psychotropic substance”, “qualified pharmacist” (regulation 2)
- Schedule: Regulated active ingredients (scope list)
- Amendment History (from timeline provided): SL 831/2023 (18 Dec 2023); amended by S 818/2024 (1 Nov 2024); amended by S 766/2025 (1 Dec 2025); current version as at 27 Mar 2026
What Is This Legislation About?
The Health Products (Active Ingredients) Regulations 2023 (“Active Ingredients Regulations”) form part of Singapore’s regulatory framework for health products under the Health Products Act 2007. In plain language, these Regulations control the manufacture, importation, wholesale dealing, storage, transport, and documentation of “regulated active ingredients” used in health products. The central policy objective is to reduce the risk of harm to patients and consumers arising from adulterated, counterfeit, or otherwise unwholesome active ingredients.
The Regulations do this by (i) prohibiting certain conduct involving active ingredients that do not meet quality and integrity expectations; (ii) requiring licences for key activities (manufacture, import, and wholesale) for persons who deal with regulated active ingredients; and (iii) imposing operational duties on licensees and other persons, including record-keeping, information transmission, and recall notification. They also provide for certification regimes, particularly relevant where active ingredients are intended for export.
For practitioners, the Regulations are best understood as a compliance and risk-management instrument: they translate broad quality and safety goals into concrete legal duties, backed by enforcement powers and procedural requirements. The Schedule’s list of regulated active ingredients is therefore critical to determining whether the Regulations apply to a particular substance or supply chain.
What Are the Key Provisions?
1) Prohibitions against dealing with substandard or fraudulent active ingredients (Part 2). The Regulations create offences or compliance breaches around “adulterated, counterfeit or unwholesome” active ingredients. Specifically, regulation 4 prohibits the manufacture of adulterated, counterfeit or unwholesome active ingredients. Regulation 5 prohibits import or supply of such active ingredients. While the extract does not reproduce the full operative definitions of “adulterated”, “counterfeit”, or “unwholesome”, the structure indicates that the Regulations target both quality failures (adulteration/unwholesomeness) and integrity failures (counterfeiting). Practically, this means that a supplier cannot rely on commercial assurances alone; they must ensure that the active ingredient meets the regulatory standard and is genuine.
2) Licensing requirements for manufacture, import, and wholesale (Part 3). Part 3 is the compliance backbone. Regulations 6 to 8 require licences for: (a) manufacture of active ingredients (regulation 6); (b) import of active ingredients (regulation 7); and (c) wholesale of active ingredients (regulation 8). The Regulations also include carve-outs: regulations 9 to 11 identify persons who do not require manufacturer’s, importer’s, or wholesaler’s licences, respectively. These exemptions are often where practitioners need to focus: for example, certain limited activities, transitional arrangements, or activities performed by particular categories of persons may fall outside licensing requirements.
3) Licensing criteria and issue of licences (Division 2 of Part 3). Regulations 12 to 14 set out requirements for the issue of manufacturer’s, importer’s, and wholesaler’s licences. Although the extract does not provide the full text of these licensing criteria, the Regulations’ definitions strongly suggest that licence issuance is tied to compliance with recognised quality systems. The Regulations define “Good Manufacturing Practice standard” and “Good Distribution Practice standard”, which are standard-setting concepts used to evaluate whether a licensee’s processes and controls are adequate. In practice, counsel should expect that licence applications require evidence of suitable facilities, quality management systems, competent personnel, and appropriate procedures for handling and distribution.
4) Operational duties: storage, transport, supply information, records, and recall (Part 4). Part 4 imposes duties on persons dealing with active ingredients. Division 1 covers general duties in relation to storage and transport: regulation 15 addresses storage of active ingredients, and regulation 16 addresses transport. These provisions are designed to prevent degradation, contamination, mix-ups, or other risks that can compromise quality during the supply chain.
Division 2 addresses import/export/supply-specific duties. Regulations 17 and 18 deal with import and export of active ingredients that are “psychotropic substances”. This is significant because psychotropic substances are typically subject to additional controls under Singapore’s broader therapeutic product regime. Regulation 19 states “No retail supply of active ingredients”, which is a major commercial constraint: it indicates that active ingredients are not intended to be sold directly to retail consumers, and that supply should occur through regulated channels (e.g., licensed wholesale or other permitted pathways). Regulation 20 requires information that must accompany supply of an active ingredient, and regulation 21 addresses wholesale of active ingredients. Together, these provisions ensure traceability and enable downstream verification of authenticity and quality.
Division 3 imposes record-keeping and recall notification duties. Regulations 22 to 24 require duties to maintain records of: (a) manufacture (regulation 22); (b) receipt and supply (regulation 23); and (c) defects (regulation 24). Regulation 25 requires notification to the Authority concerning recall. For practitioners, this is where litigation and enforcement risk often concentrates: inadequate records or delayed recall notification can lead to regulatory action even where the underlying quality issue is later resolved.
5) Duties specific to licensees (Division 4 of Part 4). Regulations 26 to 30 impose additional duties on licensed manufacturers, importers, and wholesalers. Regulation 29 introduces the concept of a “responsible person”, which is a common regulatory mechanism to ensure accountability within an organisation. Regulation 30 addresses changes affecting licences, which is crucial for corporate governance: changes in ownership, premises, key personnel, or operational scope may require notification or approval to keep the licence valid and compliant.
6) Certificates for export and standards (Part 5). Part 5 provides for certificates. Regulation 31 sets out the application of this Part. Regulation 32 addresses certification of active ingredients intended for export. Regulations 33 and 34 relate to certificates of manufacturing standard and distribution standard, respectively. These provisions are particularly important for cross-border trade: they provide a legal pathway to demonstrate that active ingredients were manufactured and distributed in accordance with required standards, which can be essential for foreign regulators and counterparties.
7) Enforcement and procedural matters (Part 6). Regulation 35 provides that enforcement officers may conduct routine inspections. Regulation 36 addresses form and manner of applications and notices, which matters for compliance workflows and deadlines. Regulation 37 includes saving and transitional provisions, which typically preserve rights or manage the transition from prior regulatory regimes to the new framework.
How Is This Legislation Structured?
The Regulations are structured into seven main components:
Part 1 (Preliminary) contains citation, commencement, definitions, and application. Regulation 2 is particularly important because it defines key terms used throughout the Regulations, including “manufacture”, “Good Manufacturing Practice standard”, “Good Distribution Practice standard”, and “psychotropic substance”.
Part 2 sets out prohibitions against dealing with adulterated, counterfeit, or unwholesome active ingredients, covering both manufacture and import/supply.
Part 3 (Licences) is divided into: (i) Division 1 on when licences are required (and exemptions); and (ii) Division 2 on requirements for issue of licences.
Part 4 (Duties) is divided into four Divisions: storage/transport; import/export/supply; records and recall; and duties specific to licensees (including the responsible person and licence change management).
Part 5 (Certificates) establishes certification requirements for active ingredients intended for export and for manufacturing/distribution standards.
Part 6 (Miscellaneous) includes enforcement inspection powers, procedural rules for applications/notices, and transitional provisions.
The Schedule lists the regulated active ingredients. Determining whether a substance is “regulated” is often the first step in legal analysis.
Who Does This Legislation Apply To?
The Regulations apply to persons who manufacture, import, wholesale, store, transport, or otherwise deal with “regulated active ingredients” listed in the Schedule. This includes manufacturers, importers, wholesalers, and potentially other supply-chain participants who must comply with duties even if they do not hold a licence (depending on the scope of regulations 9 to 11 and the specific duties in Part 4).
In addition, the Regulations apply to activities involving psychotropic substances (regulations 17 and 18), and they impose constraints on retail supply (regulation 19). The licensing and duty framework is therefore relevant to both Singapore-based operators and, indirectly, foreign suppliers and logistics providers where their activities affect regulated dealings in Singapore.
Why Is This Legislation Important?
First, the Regulations operationalise patient safety and market integrity. By prohibiting manufacture and dealing with adulterated, counterfeit, or unwholesome active ingredients, the law targets both accidental quality failures and deliberate fraud. In a sector where active ingredients are upstream inputs for medicines and other health products, even small integrity lapses can have downstream consequences.
Second, the licensing regime creates a structured compliance environment. For practitioners, this means that regulatory risk is not limited to “bad actors”; it extends to any entity that cannot demonstrate compliance with licensing requirements and ongoing duties. The definitions of Good Manufacturing Practice and Good Distribution Practice standards signal that HSA expects alignment with recognised quality systems.
Third, the record-keeping and recall notification duties are high-impact. In enforcement scenarios, regulators typically rely on documentation to assess whether a licensee could trace products, identify defects, and act promptly. Regulation 25’s recall notification duty, together with records of defects (regulation 24), makes recall readiness a legal obligation rather than a voluntary best practice.
Related Legislation
- Health Products Act 2007
- Pharmacists Registration Act 2007 (relevant to definitions such as “qualified pharmacist”)
- Health Products (Clinical Research Materials) Regulations 2016 (relevant to the definition of “clinical research”)
- Health Products (Therapeutic Products) Regulations 2016 (relevant to the definition of “psychotropic substance”)
- Health Products (Licensing of Retail Pharmacies) Regulations 2016 (relevant to “pharmacy licence” definition)
- Health Products (Medical Devices) Regulations 2010 (relevant to “laboratory-developed test” definition)
- Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021 (relevant to “minimal manipulation” definition)
Source Documents
This article provides an overview of the Health Products (Active Ingredients) Regulations 2023 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.